• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Smith & Nephew SNATS Inc.

    6/11/26 6:14:33 AM ET
    $SNN
    Industrial Specialties
    Health Care
    Get the next $SNN alert in real time by email
    6-K 1 a9345h.htm HOLDING(S) IN COMPANY a9345h
     
     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    Form 6-K
     
    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16 under the
    Securities Exchange Act of 1934
     
    June 11, 2026
     
    Commission File Number 001-14978
     
    SMITH & NEPHEW plc
    (Registrant’s name)
     
    Building 5, Croxley Park, Hatters Lane
    Watford, England, WD18 8YE
     (Address of principal executive office)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
     
    Form 20-F  ✔         Form 40-F __
     
     
     
     
     
     
    TR-1: Standard form for notification of major holdings
     
     
    1. Issuer Details
     
    ISIN
    GB0009223206
     
    Issuer Name
    SMITH & NEPHEW PLC
     
    UK or Non-UK Issuer
    UK
     
    2. Reason for Notification
    An acquisition or disposal of voting rights
     
    3. Details of person subject to the notification obligation
     
    Name
    Cevian Capital II GP Limited
     
    City of registered office (if applicable)
    `St Helier
     
    Country of registered office (if applicable)
    Jersey
     
    4. Details of the shareholder

    Name
     
    City of registered office
     
    Country of registered office
     
    Aurora Nominees Limited
     
    London
     
    England
     
     
    5. Date on which the threshold was crossed or reached
     
    08-Jun-2026
     
    6. Date on which Issuer notified
     
    10-Jun-2026
     
    7. Total positions of person(s) subject to the notification obligation
     
     
    % of voting rights attached to shares (total of 8.A)
     
    % of voting rights through financial instruments (total of 8.B 1 + 8.B 2)
     
    Total of both in % (8.A + 8.B)
     
    Total number of voting rights held in issuer
     
    Resulting situation on the date on which threshold was crossed or reached
     
    12.074433
     
    0.000000
     
    12.074433
     
    102493881
     
    Position of previous notification (if applicable)
     
    11.183442
     
    0.000000
     
    11.183442
     
     
     
    8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
     
    8A. Voting rights attached to shares
    Class/Type of shares ISIN code(if possible)
     
    Number of direct voting rights (DTR5.1)
     
    Number of indirect voting rights (DTR5.2.1)
     
    % of direct voting rights (DTR5.1)
     
    % of indirect voting rights (DTR5.2.1)
     
    GB0009223206
     
    0
     
    102493881
     
    0.000000
     
    12.074433
     
    Sub Total 8.A
     
    102493881
     
    12.074433%
     
     
    8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
    Type of financial instrument
     
    Expiration date
     
    Exercise/conversion period
     
    Number of voting rights that may be acquired if the instrument is exercised/converted
     
    % of voting rights
     
     
     
     
     
     
     
    Sub Total 8.B1
     
     
     
     
     
    8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
    Type of financial instrument
     
    Expiration date
     
    Exercise/conversion period
     
    Physical or cash settlement
     
    Number of voting rights
     
    % of voting rights
     
     
     
     
     
     
     
     
    Sub Total 8.B2
     
     
     
     
     
    9. Information in relation to the person subject to the notification obligation
     
    2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)
     
     
     
     
    Ultimate controlling person
     
    Name of controlled undertaking
     
    % of voting rights if it equals or is higher than the notifiable threshold
     
    % of voting rights through financial instruments if it equals or is higher than the notifiable threshold
     
    Total of both if it equals or is higher than the notifiable threshold
     
    Cevian Capital II G.P. Limited
     
    Cevian Capital II Master Fund L.P.
     
    10.889586
     
     
    10.889586%
     
    Cevian Capital II G.P. Limited
     
    Cevian Capital II Co-Investment - Series P L.P.
     
    1.184847
     
     
    1.184847%
     
     
    10. In case of proxy voting
     
    Name of the proxy holder
     
     
    The number and % of voting rights held
     
     
    The date until which the voting rights will be held
     
     
    If date does not apply, explain below
     
     
    11. Additional Information
     
    Cevian Capital II G.P. Limited acts as general partner for Cevian Capital II Master Fund L.P. and Cevian
     
    Capital II Co-Investment - Series P L.P.
     
    The legal owner of the shares is Aurora Nominees Limited (acting as nominee), which holds the shares on behalf of UBS AG (acting as custodian).
     
     
    12. Date of Completion
     
    10-Jun-2026
     
    13. Place Of Completion
     
    Jersey
     
     
     
     
     
     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     
     
     
     
     
    Smith & Nephew plc
     
     
    (Registrant)
     
     
     
     
     
     
    Date: June 11, 2026
    By:
    /s/ Helen Barraclough
     
     
    Helen Barraclough
     
     
    Company Secretary
    Get the next $SNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNN

    DatePrice TargetRatingAnalyst
    6/4/2026Buy → Hold
    Kepler
    12/15/2025Outperform → Sector Perform
    RBC Capital Mkts
    10/14/2025$37.50Outperform → Mkt Perform
    Bernstein
    4/25/2025Buy → Hold
    HSBC Securities
    3/12/2025Buy → Neutral
    UBS
    11/6/2024Buy → Hold
    Berenberg
    11/1/2024Buy → Hold
    Deutsche Bank
    7/24/2024Buy
    Deutsche Bank
    More analyst ratings

    $SNN
    SEC Filings

    View All

    SEC Form 6-K filed by Smith & Nephew SNATS Inc.

    6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

    6/17/26 6:38:33 AM ET
    $SNN
    Industrial Specialties
    Health Care

    SEC Form 6-K filed by Smith & Nephew SNATS Inc.

    6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

    6/11/26 6:14:33 AM ET
    $SNN
    Industrial Specialties
    Health Care

    SEC Form 6-K filed by Smith & Nephew SNATS Inc.

    6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

    6/4/26 11:24:22 AM ET
    $SNN
    Industrial Specialties
    Health Care

    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower

    Issued on behalf of Conexeu Sciences Inc.A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.RENO, Nev., June 16, 2026 /CNW/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 1

    6/16/26 8:15:00 AM ET
    $ABBV
    $ESTA
    $SNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Dental Instruments

    A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus

    NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (NASDAQ:CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further into manufacturing scale-up and regulatory preparation as it works toward a planned first-quarter 2027 510(k) submission. Companies mentioned: Conexeu Scien

    6/9/26 9:54:59 AM ET
    $IART
    $MDXG
    $SNN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Specialties

    Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty

    Smith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings. These early cases represent the first use of CORI XT Platform across both knee and shoulder arthroplasty a

    6/8/26 1:22:55 PM ET
    $SNN
    Industrial Specialties
    Health Care

    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Smith & Nephew downgraded by Kepler

    Kepler downgraded Smith & Nephew from Buy to Hold

    6/4/26 8:44:15 AM ET
    $SNN
    Industrial Specialties
    Health Care

    Smith & Nephew downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded Smith & Nephew from Outperform to Sector Perform

    12/15/25 9:57:35 AM ET
    $SNN
    Industrial Specialties
    Health Care

    Smith & Nephew downgraded by Bernstein with a new price target

    Bernstein downgraded Smith & Nephew from Outperform to Mkt Perform and set a new price target of $37.50

    10/14/25 8:42:59 AM ET
    $SNN
    Industrial Specialties
    Health Care

    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: Plc Nephew & Smith claimed ownership of 5,428,680 units of Class A Common Stock and claimed ownership of 16,534,814 units of Class B Common Stock

    3 - SMITH & NEPHEW PLC (0000845982) (Reporting)

    2/12/21 6:00:30 AM ET
    $SNN
    Industrial Specialties
    Health Care

    $SNN
    Leadership Updates

    Live Leadership Updates

    View All

    Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

    Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.  As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value.  Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy

    6/23/25 8:00:00 AM ET
    $LAZ
    $SNN
    Investment Managers
    Finance
    Industrial Specialties
    Health Care

    Cadence Welcomes Bob White to Board of Directors

    STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors.  Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM.  He recent

    9/12/24 10:57:00 AM ET
    $SNN
    Industrial Specialties
    Health Care

    $SNN
    Financials

    Live finance-specific insights

    View All

    Smith+Nephew completes acquisition of Integrity Orthopaedics; establishes unrivalled portfolio for shoulder repair

    Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces it has completed the acquisition of Integrity Orthopaedics, further strengthening its sports medicine shoulder repair business with the most comprehensive suite of technologies available for rotator cuff repair (RCR). Integrity Orthopaedics is a US‑based, early‑stage commercial developer of Tendon Seam™, an innovative and disruptive biomechanical RCR system designed to significantly reduce re‑tear rates and improve patient outcomes versus the current standard of care. Tendon Seam™ allows for a novel repair stitch configuration with multiple points of fixation. Its patented microanchors, continuous sutu

    1/21/26 12:15:00 PM ET
    $SNN
    Industrial Specialties
    Health Care

    Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research

    New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc

    3/3/25 8:20:00 AM ET
    $SNN
    Industrial Specialties
    Health Care

    Wound Care Market Will Reach USD 31.81 Billion by 2030 on the Back of Growth in the North American Market

    New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra

    8/29/22 3:20:00 PM ET
    $SNN
    Industrial Specialties
    Health Care

    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

    SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

    7/9/24 12:00:10 PM ET
    $SNN
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)

    2/3/21 1:13:21 PM ET
    $SNN
    Industrial Specialties
    Health Care